BMJ Case Reports 2009; doi:10.1136/bcr.08.2008.0691
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report

  1. Joaquin De Haro,
  2. Aurora Florez,
  3. Jose Luis Fernandez,
  4. Francisco Acin
  1. Hospital Universitario Getafe, Angiology and Vascular Surgery, Carretera de Toledo Km 12500, Getafe, 28905, Spain
  1. Joaquin De Haro, deharojoaquin{at}
  • Published 12 May 2009


Buerger disease (thromboangiitis obliterans) is a non-atherosclerotic segmental inflammatory disease strongly associated with tobacco use, and it affects small and medium-sized blood vessels in the upper and lower extremities. The only known treatment for this disease is complete discontinuation of tobacco use. This report describes the case history of a woman with Buerger disease treated with the oral dual endothelin receptor antagonist bosentan. It is believed that this is the first description in the literature of this use for bosentan.


  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article